Hans Deckmyn

List of Publications by Year
in descending order

209	9,587	28274 55	45317 90
papers	citations	h-index	g-index

212	212	212	7732
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The von Willebrand Factor A1 domain mediates thromboinflammation, aggravating ischemic stroke outcome in mice. Haematologica, 2021, 106, 819-828.	3.5	18
2	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
3	Differential regulation of the platelet GPIbâ€IX complex by antiâ€GPIbÎ² antibodies. Journal of Thrombosis and Haemostasis, 2021, 19, 2044-2055.	3.8	7
4	Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance. Haematologica, 2020, 105, 498-507.	3.5	154
5	Crucial Role for Endothelial Cell Î±2Î²1 Integrin Receptor Clustering in Collagenâ€Induced Angiogenesis. Anatomical Record, 2020, 303, 1604-1618.	1.4	9
6	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
7	Antiâ€ADAMTS13 autoantibodies in immuneâ€mediated thrombotic thrombocytopenic purpura do not hamper ELISAâ€based quantification of ADAMTS13 antigen. Journal of Thrombosis and Haemostasis, 2020, 18, 985-990.	3.8	12
8	Selective inhibition of TGF-Î²1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. Nature Communications, 2020, 11, 4545.	12.8	94
9	Sickle cell disease and COVIDâ€19: Atypical presentations and favorable outcomes. EJHaem, 2020, 1, 338-341.	1.0	14
10	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood, 2020, 136, 353-361.	1.4	35
11	von Willebrand factor increases in experimental cerebral malaria but is not essential for lateâ€stage pathogenesis in mice. Journal of Thrombosis and Haemostasis, 2020, 18, 2377-2390.	3.8	2
12	Glycoprotein VI is not a Functional Platelet Receptor for Fibrin Formed in Plasma or Blood. Thrombosis and Haemostasis, 2020, 120, 977-993.	3.4	11
13	Appropriation of GPIbÎ± from platelet-derived extracellular vesicles supports monocyte recruitment in systemic inflammation. Haematologica, 2020, 105, 1248-1261.	3.5	65
14	Antibodies that conformationally activate ADAMTS13 allosterically enhance metalloprotease domain function. Blood Advances, 2020, 4, 1072-1080.	5.2	28
15	Acquired von Willebrand syndrome in patients on long-term left ventricular assist device support: Results of a Belgian center. Thrombosis Research, 2019, 184, 77-80.	1.7	1
16	von Willebrand factor in experimental malariaâ€associated acute respiratory distress syndrome. Journal of Thrombosis and Haemostasis, 2019, 17, 1372-1383.	3.8	8
17	Exposure of von Willebrand Factor on Isolated Hepatocytes Promotes Tethering of Platelets to the Cell Surface. Transplantation, 2019, 103, 1630-1638.	1.0	3
18	Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients. Haematologica, 2019, 104, 1268-1276.	3.5	5

#	Article	IF	Citations
19	High and longâ€term von Willebrand factor expression after Sleeping Beauty transposonâ€mediated gene therapy in a mouse model of severe von Willebrand disease. Journal of Thrombosis and Haemostasis, 2018, 16, 592-604.	3.8	18
20	Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaqueâ€“triggered thrombus formation in humans. Blood, 2018, 131, 2605-2616.	1.4	74
21	Anti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of Pregnancy-Onset Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open, 2018, 02, e8-e15.	1.4	11
22	An open conformation of ADAMTSâ€13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2018, 16, 378-388.	3.8	72
23	Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist deviceâ€induced acquired von Willebrand syndrome. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 762-766.	2.3	6
24	Functional Genomics for the Identification of Modulators of Platelet-Dependent Thrombus Formation. TH Open, 2018, 02, e272-e279.	1.4	2
25	von Willebrand factor deficiency does not influence angiotensin II-induced abdominal aortic aneurysm formation in mice. Scientific Reports, 2018, 8, 16645.	3.3	4
26	Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 2018, 118, 1729-1742.	3.4	24
27	Preparation and characterization of large-format macroporous cryogel disks for use in affinity chromatography and biotechnological applications. Analytical and Bioanalytical Chemistry, 2018, 410, 7765-7771.	3.7	1
28	Childâ€onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13. European Journal of Haematology, 2018, 101, 191-199.	2.2	4
29	Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation. Thrombosis and Haemostasis, 2018, 118, 1397-1408.	3.4	13
30	Deletion of GARP on mouse regulatory T cells is not sufficient to inhibit the growth of transplanted tumors. Cellular Immunology, 2018, 332, 129-133.	3.0	8
31	Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets. Blood, 2018, 131, 787-796.	1.4	54
32	Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology. Blood, 2018, 132, 222-222.	1.4	0
33	Anti-CUB1 or Anti-Spacer Antibodies That Increase ADAMTS13 Activity Act By Allosterically Enhancing Metalloprotease Domain Function. Blood, 2018, 132, 23-23.	1.4	5
34	Long-Term Prevention of Congenital Thrombotic Thrombocytopenic Purpura in ADAMTS13 Knockout Mice by Sleeping Beauty Transposon-Mediated Gene Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 836-844.	2.4	19
35	Development and screening of epoxyâ€spacerâ€phage cryogels for affinity chromatography: Enhancing the binding capacity. Journal of Separation Science, 2017, 40, 2575-2583.	2.5	4
36	N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. Blood, 2017, 129, 1030-1038.	1.4	53

#	Article	IF	Citations
37	Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice. Journal of Thrombosis and Haemostasis, 2017, 15, 2432-2442.	3.8	14
38	Neutrophil extracellular traps in ischemic stroke thrombi. Annals of Neurology, 2017, 82, 223-232.	5.3	339
39	The role of platelet and endothelial GARP in thrombosis and hemostasis. PLoS ONE, 2017, 12, e0173329.	2.5	27
40	Inhibitors of Platelet Adhesion to VWF and Collagen. , 2017, , 1313-1323.		2
41	Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS ONE, 2017, 12, e0179258.	2.5	27
42	Platelet sequestration and activation during GalTKO.hCD46 pig lung perfusion by human blood is primarily mediated by GPIb, GPIIb/IIIa, and von Willebrand Factor. Xenotransplantation, 2016, 23, 222-236.	2.8	26
43	Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice. Stroke, 2016, 47, 2419-2422.	2.0	48
44	ADAMTS13-mediated thrombolysis of t-PAâ€“resistant occlusions in ischemic stroke in mice. Blood, 2016, 127, 2337-2345.	1.4	138
45	ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura â€“ current perspectives and new treatment strategies. Expert Review of Hematology, 2016, 9, 209-221.	2.2	23
46	Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2016, 11, e0160388.	2.5	14
47	Platelet-derived VWF is not essential for normal thrombosis and hemostasis but fosters ischemic stroke injury in mice. Blood, 2015, 126, 1715-1722.	1.4	65
48	Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTSâ€13. Journal of Thrombosis and Haemostasis, 2015, 13, 2063-2075.	3.8	58
49	Desmopressin treatment improves platelet function under flow in patients with postoperative bleeding. Journal of Thrombosis and Haemostasis, 2015, 13, 1503-1513.	3.8	21
50	Platelets from flowing blood attach to the inflammatory chemokine CXCL16 expressed in the endothelium of the human vessel wall. Thrombosis and Haemostasis, 2015, 114, 297-312.	3.4	22
51	Artificial MiRNA Knockdown of Platelet Glycoprotein Ibî±: A Tool for Platelet Gene Silencing. PLoS ONE, 2015, 10, e0132899.	2.5	0
52	Blockade of Glycoproteins Ib and IIb/IIIa Reduces Platelet Sequestration and PVR Rise in a Xenogeneic Lung Perfusion Model. Journal of Heart and Lung Transplantation, 2015, 34, S274.	0.6	0
53	Choline Transporter-Like Protein-2. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1616-1622.	2.4	33
54	The novel ADAMTS13â€p.D187H mutation impairs ADAMTS13 activity and secretion and contributes to thrombotic thrombocytopenic purpura in mice. Journal of Thrombosis and Haemostasis, 2015, 13, 283-292.	3.8	17

#	Article	IF	Citations
55	Pig-to-Baboon Liver Xenoperfusion Utilizing GalTKO.hCD46 Pigs and Glycoprotein Ib Blockade.. Transplantation, 2014, 98, 413.	1.0	0
56	Pigâ€toâ€baboon liver xenoperfusion utilizing GalTKO.hCD46 pigs and glycoprotein Ib blockade. Xenotransplantation, 2014, 21, 274-286.	2.8	19
57	Single Particle Tracking of ADAMTS13 (A Disintegrin and Metalloprotease with Thrombospondin Type-1) Tj ETQq1 1 0.784314 rgBT /Ove 2014, 289, 8903-8915.	3.4	1
58	Affinity Comparison of p3 and p8 Peptide Displaying Bacteriophages Using Surface Plasmon Resonance. Analytical Chemistry, 2013, 85, 10075-10082.	6.5	30
59	Lung xenogenic injury: does anticoagulation help?. Xenotransplantation, 2013, 20, 47-48.	2.8	0
60	Patient autoantibodies induce platelet destruction signals via raft-associated glycoprotein IbÂ and Fc RIIa in immune thrombocytopenia. Haematologica, 2013, 98, e70-e72.	3.5	18
61	Platelet interaction with von Willebrand factor is enhanced by shear-induced clustering of glycoprotein IbÂ. Haematologica, 2013, 98, 1810-1818.	3.5	24
62	New Insights into von Willebrand Disease and Platelet Function. Seminars in Thrombosis and Hemostasis, 2012, 38, 55-63.	2.7	39
63	Identification of a Small Molecule That Modulates Platelet Glycoprotein Ib-von Willebrand Factor Interaction. Journal of Biological Chemistry, 2012, 287, 9461-9472.	3.4	13
64	Improved platelet survival after cold storage by prevention of glycoprotein IbÂ clustering in lipid rafts. Haematologica, 2012, 97, 1873-1881.	3.5	30
65	GPIb and GPIIb/IIIa Receptors Regulate Activation and Sequestration of Human Platelets in a Xenogenic Pig Lung Perfusion Model. Transplantation, 2012, 94, 69.	1.0	0
66	Inhibition of von Willebrand factorâ€“platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons. Blood, 2012, 120, 3611-3614.	1.4	40
67	Model systems of genetically modified platelets. Blood, 2012, 119, 1634-1642.	1.4	19
68	An integrated fragment based screening approach for the discovery of small molecule modulators of the VWFâ€“GPIbÎ± interaction. Chemical Communications, 2012, 48, 11349.	4.1	11
69	Blood platelet biochemistry. Thrombosis Research, 2012, 129, 245-249.	1.7	69
70	Inhibitors of the Interactions Between Collagen and Its Receptors on Platelets. Handbook of Experimental Pharmacology, 2012, , 311-337.	1.8	11
71	295 Combined aGPIb and aGPIIb/IIIa Blockade Prevents Platelet Sequestration in a Pig-to-Human Lung Perfusion Model. Journal of Heart and Lung Transplantation, 2012, 31, S106.	0.6	1
72	Laser-induced primary and secondary hemostasis dynamics and mechanisms in relation to selective photothermolysis of port wine stains. Journal of Dermatological Science, 2011, 63, 139-147.	1.9	26

#	Article	IF	Citations
73	295 Blocking GP1b-vWF Interaction by Anti-GP1b Fab Reduces Activation and Sequestration of Platelets in a Xenogeneic Pig Lung Perfusion Model. Journal of Heart and Lung Transplantation, 2011, 30, S103.	0.6	2
74	Platelet adhesion to collagen. Thrombosis Research, 2011, 127, S26-S29.	1.7	121
75	Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood, 2011, 117, 651-660.	1.4	62
76	The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib. Blood, 2011, 117, 4999-5008.	1.4	32
77	In vivo von Willebrand factor size heterogeneity in spite of the clinical deficiency of ADAMTS-13. Journal of Thrombosis and Haemostasis, 2011, 9, 2506-2508.	3.8	9
78	Platelets at work in primary hemostasis. Blood Reviews, 2011, 25, 155-167.	5.7	354
79	Local Elongation of Endothelial Cell-anchored von Willebrand Factor Strings Precedes ADAMTS13 Protein-mediated Proteolysis. Journal of Biological Chemistry, 2011, 286, 36361-36367.	3.4	46
80	Apparent heterogeneity in the pIII-peptide fusion protein in single-phage clones isolated from peptide libraries. Protein Engineering, Design and Selection, 2011, 24, 721-726.	2.1	1
81	Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio) Tj ETQq1 1 0.784314 rgBT /Ov	1.4	104
82	The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of platelet-decorated VWF strings in vivo. Journal of Thrombosis and Haemostasis, 2010, 8, 2305-2312.	3.8	31
83	Binding of von Willebrand Factor to Collagen and Glycoprotein Ibî±, But Not to Glycoprotein IIb/IIIa, Contributes to Ischemic Stroke in Miceâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1949-1951.	2.4	63
84	Platelet physiology and antiplatelet agents. Clinical Chemistry and Laboratory Medicine, 2010, 48, S3-13.	2.3	11
85	Roles of Src-like adaptor protein 2 (SLAP-2) in GPVI-mediated platelet activation. Thrombosis Research, 2010, 126, e276-e285.	1.7	13
86	Development of a high-throughput ELISA assay for platelet function testing using platelet-rich plasma or whole blood. Thrombosis and Haemostasis, 2010, 104, 392-401.	3.4	12
87	Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood, 2010, 116, 4646-4656.	1.4	90
88	Humanization by Resurfacing. , 2010, , 341-353.		1
89	The Novel S527F Mutation in the Integrin Î²3 Chain Induces a High Affinity Î±IIbÎ²3 Receptor by Hindering Adoption of the Bent Conformation. Journal of Biological Chemistry, 2009, 284, 14914-14920.	3.4	16
90	Von Willebrand Factor: Drug and Drug Target. Cardiovascular & Hematological Disorders Drug Targets, 2009, 9, 9-20.	0.7	24

#	Article	IF	Citations
91	Chromato-panning: an efficient new mode of identifying suitable ligands from phage display libraries. BMC Biotechnology, 2009, 9, 21.	3.3	28
92	Synthesis and modifications of a small library of 1,4-benzodiazepin-3-ones toward potential inhibitors of the collagenâ€"von Willebrand Factor interaction. Tetrahedron, 2009, 65, 4521-4529.	1.9	7
93	On the interaction of fluorophore-encapsulating PEGylated lecithin liposomes with hamster and human platelets. Microvascular Research, 2009, 78, 57-66.	2.5	14
94	Platelets and PEGylated lecithin liposomes: When stealth is allegedly picked up on the radar (and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.5	5
95	Laboratory Diagnosis and Molecular Classification of von Willebrand Disease. Acta Haematologica, 2009, 121, 71-84.	1.4	41
96	ADAMTS13 in Health and Disease. Acta Haematologica, 2009, 121, 183-185.	1.4	16
97	Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34+ cells are functionally active in an ex vivo flow model of thrombosis. Blood, 2009, 114, 5044-5051.	1.4	23
98	Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura. Blood, 2009, 114, 4749-4752.	1.4	19
99	Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood, 2009, 113, 4754-4762.	1.4	69
100	Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood, 2009, 113, 3600-3603.	1.4	148
101	von Willebrand factor to the rescue. Blood, 2009, 113, 5049-5057.	1.4	138
102	Fluorescent labeling of platelets with polyanionic fluorescein derivatives. , 2009, 31, 227-32.		4
103	Inherited traits affecting platelet function. Blood Reviews, 2008, 22, 155-172.	5.7	105
104	Multiple ways to switch platelet integrins on and off. Journal of Thrombosis and Haemostasis, 2008, 6, 1253-1261.	3.8	80
105	Antiplatelet drugs. British Journal of Haematology, 2008, 142, 515-528.	2.5	53
106	The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thrombosis and Haemostasis, 2008, 100, 670-677.	3.4	62
107	Restoration of Plasma von Willebrand Factor Deficiency Is Sufficient to Correct Thrombus Formation After Gene Therapy for Severe von Willebrand Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1621-1626.	2.4	64
108	Functional Genomics in Zebrafish Permits Rapid Characterization of Novel Platelet Membrane Proteins. Blood, 2008, 112, 2860-2860.	1.4	0

#	Article	IF	Citations
109	The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thrombosis and Haemostasis, 2008, 100, 670-7.	3.4	20
110	Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential. Current Pharmaceutical Design, 2007, 13, 2684-2697.	1.9	46
111	Paratope and Epitope Mapping of the Antithrombotic Antibody 6B4 in Complex with Platelet Glycoprotein Ibî±. Journal of Biological Chemistry, 2007, 282, 23517-23524.	3.4	18
112	Activation of î±IIbî²3 is a sufficient but also an imperative prerequisite for activation of î±2î²1 on platelets. Blood, 2007, 109, 595-602.	1.4	43
113	Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure*. Critical Care Medicine, 2007, 35, 2375-2382.	0.9	167
114	False positive results in chimeraplasty for von Willebrand Disease. Thrombosis Research, 2007, 119, 93-104.	1.7	13
115	Macroporous monolithic gels, cryogels, with immobilized phages from phage-display library as a new platform for fast development of affinity adsorbent capable of target capture from crude feeds. Journal of Biotechnology, 2007, 131, 293-299.	3.8	64
116	Glycoprotein Ibî± inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thrombosis and Haemostasis, 2007, 97, 435-443.	3.4	49
117	Type 2B von Willebrand disease in seven individuals from three different families: Phenotypic and genotypic characterization. Thrombosis and Haemostasis, 2007, 98, 251-254.	3.4	8
118	The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibî±. Thrombosis and Haemostasis, 2007, 98, 178-185.	3.4	10
119	ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. British Journal of Haematology, 2007, 138, 534-540.	2.5	135
120	Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor - collagen interaction in baboons. Thrombosis and Haemostasis, 2007, 98, 1343-1349.	3.4	12
121	Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thrombosis and Haemostasis, 2007, 97, 435-43.	3.4	14
122	The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibalpha. Thrombosis and Haemostasis, 2007, 98, 178-85.	3.4	4
123	Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization. Thrombosis and Haemostasis, 2007, 98, 251-4.	3.4	1
124	Shielding of the A1 Domain by the Dâ€²D3 Domains of von Willebrand Factor Modulates Its Interaction with Platelet Glycoprotein Ib-IX-V. Journal of Biological Chemistry, 2006, 281, 4699-4707.	3.4	115
125	Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Molecular Immunology, 2006, 43, 1243-1257.	2.2	54
126	Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood, 2006, 107, 4728-4736.	1.4	66

#	Article	IF	Citations
127	When collagen meets VWF. Blood, 2006, 108, 3628-3628.	1.4	3
128	Role of glycoprotein Ib? in phagocytosis of platelets by macrophages. Transfusion, 2006, 46, 2090-2099.	1.6	28
129	ADAMTSâ€13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. Journal of Thrombosis and Haemostasis, 2006, 4, 955-962.	3.8	86
130	Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease. British Journal of Haematology, 2006, 133, 655-663.	2.5	18
131	Immobilised peptide displaying phages as affinity ligands. Journal of Chromatography A, 2006, 1101, 79-85.	3.7	46
132	Von Willebrand Factor Antigen Latex Immunoassays are Affected to a Different Extent by Rheumatoid Factor. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 242-243.	1.7	4
133	Matrix-specific Suppression of Integrin Activation in Shear Stress Signaling. Molecular Biology of the Cell, 2006, 17, 4686-4697.	2.1	139
134	Paratope Determination of the Antithrombotic Antibody 82D6A3 Based on the Crystal Structure of Its Complex with the von Willebrand Factor A3-Domain. Journal of Biological Chemistry, 2006, 281, 2225-2231.	3.4	23
135	Rational humanization of the powerful antithrombotic anti-GPIbÎ± antibody: 6B4. Thrombosis and Haemostasis, 2006, 96, 671-684.	3.4	25
136	Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIbÎ±. Thrombosis and Haemostasis, 2006, 96, 774-780.	3.4	30
137	Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thrombosis and Haemostasis, 2006, 96, 671-84.	3.4	9
138	Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba. Thrombosis and Haemostasis, 2006, 96, 774-80.	3.4	12
139	The von Willebrand factor self-association is modulated by a multiple domain interaction. Journal of Thrombosis and Haemostasis, 2005, 3, 552-561.	3.8	45
140	Plasma glycocalicin as a source of GPIbÎ± in the von Willebrand factor ristocetin cofactor ELISA. Thrombosis and Haemostasis, 2005, 93, 165-171.	3.4	25
141	Two Functional Active Conformations of the Integrin Î±2Î²1, Depending on Activation Condition and Cell Type. Journal of Biological Chemistry, 2005, 280, 36873-36882.	3.4	38
142	Synergistic Effect of Thrombin on Collagen-Induced Platelet Procoagulant Activity Is Mediated Through Protease-Activated Receptor-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1499-1505.	2.4	78
143	How does agkicetin-C bind on platelet glycoprotein IbÎ± and achieve its platelet effects?. Toxicon, 2005, 45, 561-570.	1.6	16
144	Platelet integrin Î±2 I-domain specific antibodies produced via domain specific DNA vaccination combined with variable gene phage display. Thrombosis and Haemostasis, 2005, 94, 1318-1326.	3.4	1

#	Article	IF	Citations
145	Phenotypic Correction of von Willebrand Disease Type 3 Blood-Derived Endothelial Cells with Lentiviral Vectors Expressing von Willebrand Factor.. Blood, 2005, 106, 5522-5522.	1.4	0
146	Platelet integrin alpha2 I-domain specific antibodies produced via domain specific DNA vaccination combined with variable gene phage display. Thrombosis and Haemostasis, 2005, 94, 1318-26.	3.4	1
147	The Hemostatic System. Current Medicinal Chemistry, 2004, 11, 2245-2260.	2.4	145
148	Principal Role of Glycoprotein VI in Î±2Î²1 and Î±IIbÎ²3 Activation During Collagen-Induced Thrombus Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1727-1733.	2.4	86
149	Identification of Residues within Human Glycoprotein VI Involved in the Binding to Collagen. Journal of Biological Chemistry, 2004, 279, 52293-52299.	3.4	53
150	New model of transient strain-dependent autoimmune thrombocytopenia in mice immunized with rat platelets. Experimental Hematology, 2004, 32, 87-94.	0.4	23
151	Experimental indication for the existence of multiple Trp rotamers in von Willebrand Factor A3 domain. Proteins: Structure, Function and Bioinformatics, 2004, 57, 596-601.	2.6	7
152	The GPIbÎ±â€“thrombin interaction: far from crystal clear. Trends in Molecular Medicine, 2004, 10, 33-39.	6.7	27
153	Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood, 2004, 103, 1333-1341.	1.4	175
154	Monoclonal antibody IAC-1 is specific for activated Î±2Î²1 and binds to amino acids 199 to 201 of the integrin Î±2 I-domain. Blood, 2004, 104, 390-396.	1.4	36
155	Human Platelet Glycoprotein VI: Identification of Residues Involved in the Binding to Collagen.. Blood, 2004, 104, 1550-1550.	1.4	13
156	Integrin αIIbβ3 and shear-dependent action of glycoprotein ibα stimulate platelet-dependent thrombin formation in stirred plasma. Translational Research, 2003, 141, 350-358.	2.3	9
157	Von Willebrand Factor But Not Î±-Thrombin Binding to Platelet Glycoprotein IbÎ± Is Influenced by the HPA-2 Polymorphism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1302-1307.	2.4	39
158	A Consensus Tetrapeptide Selected by Phage Display Adopts the Conformation of a Dominant Discontinuous Epitope of a Monoclonal Anti-VWF Antibody That Inhibits the von Willebrand Factor-Collagen Interaction. Journal of Biological Chemistry, 2003, 278, 37815-37821.	3.4	35
159	The role of VWF-collagen interaction in acute platelet thrombus formation. Drugs of the Future, 2003, 28, 61.	0.1	4
160	A Reliable von Willebrand Factor: Ristocetin Cofactor Enzyme-Linked Immunosorbent Assay to Differentiate between Type 1 and Type 2 von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2002, 28, 161-166.	2.7	16
161	Shear-dependent morphology of von Willebrand factor bound to immobilized collagen. Blood, 2002, 99, 2070-2076.	1.4	40
162	Inhibition of the von Willebrand (VWF)â€“collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood, 2002, 99, 3623-3628.	1.4	112

#	Article	IF	Citations
163	The Parasitic Hematophagous Worm Haemonchus contortus Inhibits Human Platelet Aggregation and Adhesion: Partial Purification of a Platelet Inhibitor. Thrombosis and Haemostasis, 2002, 87, 899-904.	3.4	11
164	Inhibition of Platelet Glycoprotein Ib, Glycoprotein IIb/IIIa, or Both by Monoclonal Antibodies Prevents Arterial Thrombosis in Baboons. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 323-328.	2.4	65
165	The parasitic hematophagous worm Haemonchus contortus inhibits human platelet aggregation and adhesion: partial purification of a platelet inhibitor. Thrombosis and Haemostasis, 2002, 87, 899-904.	3.4	3
166	A Monoclonal Antibody to Platelet Type III Collagen-binding Protein (TIIICBP) Binds to Blood and Vascular Cells, and Inhibits Platelet Vessel-wall Interactions. Thrombosis and Haemostasis, 2001, 86, 694-701.	3.4	11
167	Fc-receptor Dependent Platelet Aggregation Induced by Monoclonal Antibodies against Platelet Glycoprotein Ib or von Willebrand Factor. Thrombosis and Haemostasis, 2001, 85, 679-685.	3.4	13
168	Epitope mapping of inhibitory antibodies against platelet glycoprotein IbÎ± reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein IbÎ±. Blood, 2001, 98, 652-660.	1.4	79
169	Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces. Journal of Thrombosis and Thrombolysis, 2001, 12, 249-262.	2.1	5
170	A Reliable and Reproducible ELISA Method to Measure Ristocetin Cofactor Activity of von Willebrand Factor. Thrombosis and Haemostasis, 2000, 83, 107-113.	3.4	104
171	Antithrombotic Effect of Platelet Glycoprotein Ibâ€“Blocking Monoclonal Antibody Fab Fragments in Nonhuman Primates. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1347-1353.	2.4	119
172	A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thrombosis and Haemostasis, 2000, 83, 107-13.	3.4	18
173	Acquired Bernard-Soulier Syndrome: A Case with Necrotizing Vasculitis and Thrombosis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1999, 29, 229-236.	0.3	1
174	5 Inhibitory and activating human antiplatelet antibodies. Best Practice and Research: Clinical Haematology, 1998, 11, 343-359.	1.1	12
175	Phage displayed 6-mer mimotopes with a consensus proline absent in the minimized linear wild-type epitope. International Journal of Peptide Research and Therapeutics, 1998, 5, 159-162.	0.1	0
176	Platelet Aggregation Induced by a Monoclonal Antibody to the A1 Domain of von Willebrand Factor. Blood, 1998, 91, 3792-3799.	1.4	31
177	Platelet Aggregation Induced by a Monoclonal Antibody to the A1 Domain of von Willebrand Factor. Blood, 1998, 91, 3792-3799.	1.4	3
178	von Willebrand factor binds to native collagen VI primarily via its A1 domain. Biochemical Journal, 1997, 324, 185-191.	3.7	96
179	A Platelet-Activating Antiglycoprotein Ib Monoclonal Antibody. Blood, 1997, 90, 3807-3808.	1.4	2
180	Platelet actuation. Blood Reviews, 1995, 9, 143-156.	5.7	266

#	Article	IF	Citations
181	Functional Effects of Human Antiplatelet Antibodies. Seminars in Thrombosis and Hemostasis, 1995, 21, 46-59.	2.7	26
182	Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation.. Circulation, 1994, 90, 2203-2206.	1.6	170
183	An echistatin-like Arg-Gly-Asp (RGD)-containing sequence in the heavy chain CDR3 of a murine monoclonal antibody that inhibits human platelet glycoprotein IIb/IIIa function. British Journal of Haematology, 1994, 87, 562-571.	2.5	36
184	Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clinical Pharmacology and Therapeutics, 1994, 56, 377-388.	4.7	141
185	A Monoclonal Antibody to the Î±2 Integrin Subunit Cross-Reacts with RGD-Dependent Epitopes in Fibrinogen. Hybridoma, 1993, 12, 467-474.	0.6	1
186	MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.. Circulation, 1993, 88, 1512-1517.	1.6	165
187	Thromboxane synthase inhibitors and receptor antagonists. Cardiovascular Drugs and Therapy, 1992, 6, 29-33.	2.6	32
188	Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends in Pharmacological Sciences, 1991, 12, 158-163.	8.7	117
189	Continuous quantitative monitoring of mural, platelet-dependent, thrombus kinetics in the crushed rat femoral vein. Thrombosis and Haemostasis, 1991, 65, 425-31.	3.4	4
190	Lack of Platelet Response to Collagen Associated with an Autoantibody against Glycoprotein Ia: A Novel Cause of Acquired Qualitative Platelet Dysfunction. Thrombosis and Haemostasis, 1990, 64, 074-079.	3.4	88
191	Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thrombosis and Haemostasis, 1989, 61, 479-84.	3.4	12
192	The platelet insulin receptor: Detection, partial characterization, and search for a function. Biochemical and Biophysical Research Communications, 1988, 157, 1190-1196.	2.1	83
193	Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders. Journal of Pharmacology and Experimental Therapeutics, 1988, 246, 301-7.	2.5	28
194	Prostacyclin stimulatory activity of reducing cofactors in human plasma filtrate. A potential role for uric acid. Agents and Actions, 1987, 22, 360-361.	0.7	3
195	Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.. Journal of Clinical Investigation, 1987, 80, 1435-1445.	8.2	101
196	Leukotriene B4 production by stimulated whole blood: Comparative studies with isolated polymorphonuclear cells. Biochemical and Biophysical Research Communications, 1986, 137, 334-342.	2.1	57
197	Immunomodulatory effects of treatment with naproxen in patients with rheumatic disease. Arthritis and Rheumatism, 1986, 29, 305-311.	6.7	21
198	The metabolism of phosphoinositide-derived messenger molecules. Science, 1986, 234, 1519-1526.	12.6	744

#	Article	IF	Citations
199	Guanine nucleotides stimulate soluble phosphoinositide-specific phospholipase C in the absence of membranes. Journal of Biological Chemistry, 1986, 261, 16553-8.	3.4	85
200	Thrombosis and immune disorders. Clinics in Haematology, 1986, 15, 393-412.	2.3	44
201	Influence of prostaglandin E2 and indomethacin on interferon-? production by cultured peripheral blood leukocytes of multiple sclerosis patients and healthy donors. Journal of Clinical Immunology, 1985, 5, 102-108.	3.8	13
202	Effects of thromboxane A2 on lymphocyte proliferation. Cellular Immunology, 1985, 90, 458-463.	3.0	33
203	BM 13.177, A SELECTIVE BLOCKER OF PLATELET AND VESSEL WALL THROMBOXANE RECEPTORS, IS ACTIVE IN MAN. Lancet, The, 1984, 323, 991-994.	13.7	71
204	Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2. Biochemical Pharmacology, 1984, 33, 2083-2088.	4.4	101
205	Thromboxane Synthase Inhibition Combined with Thromboxane Receptor Blockade: A Step Forward in Antithrombotic Strategy?. Thrombosis and Haemostasis, 1984, 52, 364-364.	3.4	44
206	PLATELET INHIBITORY ACTIVITY OF PROSTACYCLIN IN THE PRESENCE OF ERYTHROCYTES AS STUDIED WITH THE IMPEDANCE AGGREGOMETER. British Journal of Haematology, 1984, 57, 171-173.	2.5	5
207	Manipulation of the local thromboxane and prostacyclin balance in vivo by the antithrombotic compounds dazoxiben, acetylsalicylic acid and nafazatrom. Biochemical Pharmacology, 1983, 32, 2757-2762.	4.4	40
208	Normal mechanisms of platelet function. Clinics in Haematology, 1983, 12, 107-51.	2.3	26
209	A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thrombosis Research, 1982, 26, 389-400.	1.7	154